Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Amelia Seabold

DPhil in Translational Health Sciences

Amelia Seabold is a first year DPhil student in Translational Health Sciences. She completed her undergraduate studies and masters in city planning at Massachusetts Institute of Technology. Her research focuses on bridging the gap between academic research and practice by examining the implementation of medical diagnostics in LMICs in sub-Saharan Africa.

Her DPhil work aims to assess the feasibility of implementing a nationwide newborn screening program for sickle cell disease (SCD) in Tanzania, where SCD prevalence is particularly high. She plans to use qualitative methods including interviews and observations to better understand how a newborn screening program could be integrated into Tanzania's current health system.

Amelia has a background in wet lab biology, working on multiple CRISPR-Cas projects including the development of a low-cost point-of-care sickle cell disease diagnostic based on Cas13 in the Li Lab at the University of California, San Diego. Her previous work has also included research on the community-based responses to COVID-19 in slums and informal settlements of Freetown, Sierra Leone; Buenos Aires, Argentina; and Ahmedabad, India, as well as the effect of COVID-19 on the livelihoods of slums dwellers in Masvingo, Zimbabwe. [see publications]